Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation

Status:
Completed

Trial end date:
2005-07-01

Target enrollment:

Participant gender:

Assessment of efficacy and safety UK-390,957

Phase 2/Phase 3

Pfizer